These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29272097)

  • 1. Rational-Differential Design of Highly Specific Glycomimetic Ligands: Targeting DC-SIGN and Excluding Langerin Recognition.
    Porkolab V; Chabrol E; Varga N; Ordanini S; Sutkevičiu Tė I; Thépaut M; García-Jiménez MJ; Girard E; Nieto PM; Bernardi A; Fieschi F
    ACS Chem Biol; 2018 Mar; 13(3):600-608. PubMed ID: 29272097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective targeting of dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN) with mannose-based glycomimetics: synthesis and interaction studies of bis(benzylamide) derivatives of a pseudomannobioside.
    Varga N; Sutkeviciute I; Guzzi C; McGeagh J; Petit-Haertlein I; Gugliotta S; Weiser J; Angulo J; Fieschi F; Bernardi A
    Chemistry; 2013 Apr; 19(15):4786-97. PubMed ID: 23417900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of a glycomimetic ligand in the carbohydrate recognition domain of C-type lectin DC-SIGN. Structural requirements for selectivity and ligand design.
    Thépaut M; Guzzi C; Sutkeviciute I; Sattin S; Ribeiro-Viana R; Varga N; Chabrol E; Rojo J; Bernardi A; Angulo J; Nieto PM; Fieschi F
    J Am Chem Soc; 2013 Feb; 135(7):2518-29. PubMed ID: 23360500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second generation of fucose-based DC-SIGN ligands: affinity improvement and specificity versus Langerin.
    Andreini M; Doknic D; Sutkeviciute I; Reina JJ; Duan J; Chabrol E; Thepaut M; Moroni E; Doro F; Belvisi L; Weiser J; Rojo J; Fieschi F; Bernardi A
    Org Biomol Chem; 2011 Aug; 9(16):5778-86. PubMed ID: 21735039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis reveals selective recognition of glycans by the dendritic cell receptors DC-SIGN and Langerin.
    Holla A; Skerra A
    Protein Eng Des Sel; 2011 Sep; 24(9):659-69. PubMed ID: 21540232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unique DC-SIGN clustering activity of a small glycomimetic: A lesson for ligand design.
    Sutkeviciute I; Thépaut M; Sattin S; Berzi A; McGeagh J; Grudinin S; Weiser J; Le Roy A; Reina JJ; Rojo J; Clerici M; Bernardi A; Ebel C; Fieschi F
    ACS Chem Biol; 2014 Jun; 9(6):1377-85. PubMed ID: 24749535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
    Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
    J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A glycomimetic compound inhibits DC-SIGN-mediated HIV infection in cellular and cervical explant models.
    Berzi A; Reina JJ; Ottria R; Sutkeviciute I; Antonazzo P; Sanchez-Navarro M; Chabrol E; Biasin M; Trabattoni D; Cetin I; Rojo J; Fieschi F; Bernardi A; Clerici M
    AIDS; 2012 Jan; 26(2):127-37. PubMed ID: 22045343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Human Glycoprotein Salivary Agglutinin Inhibits the Interaction of DC-SIGN and Langerin with Oral Micro-Organisms.
    Boks MA; Gunput ST; Kosten I; Gibbs S; van Vliet SJ; Ligtenberg AJ; van Kooyk Y
    J Innate Immun; 2016; 8(4):350-61. PubMed ID: 27082983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets.
    Duinkerken S; Horrevorts SK; Kalay H; Ambrosini M; Rutte L; de Gruijl TD; Garcia-Vallejo JJ; van Kooyk Y
    Theranostics; 2019; 9(20):5797-5809. PubMed ID: 31534520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The carbohydrate recognition domain of Langerin reveals high structural similarity with the one of DC-SIGN but an additional, calcium-independent sugar-binding site.
    Chatwell L; Holla A; Kaufer BB; Skerra A
    Mol Immunol; 2008 Apr; 45(7):1981-94. PubMed ID: 18061677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High and low affinity carbohydrate ligands revealed for murine SIGN-R1 by carbohydrate array and cell binding approaches, and differing specificities for SIGN-R3 and langerin.
    Galustian C; Park CG; Chai W; Kiso M; Bruening SA; Kang YS; Steinman RM; Feizi T
    Int Immunol; 2004 Jun; 16(6):853-66. PubMed ID: 15136555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (19)F NMR-Guided Design of Glycomimetic Langerin Ligands.
    Wamhoff EC; Hanske J; Schnirch L; Aretz J; Grube M; Varón Silva D; Rademacher C
    ACS Chem Biol; 2016 Sep; 11(9):2407-13. PubMed ID: 27458873
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monovalent mannose-based DC-SIGN antagonists: targeting the hydrophobic groove of the receptor.
    Tomašić T; Hajšek D; Švajger U; Luzar J; Obermajer N; Petit-Haertlein I; Fieschi F; Anderluh M
    Eur J Med Chem; 2014 Mar; 75():308-26. PubMed ID: 24556146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New lipophilic glycomimetic DC-SIGN ligands: Stereoselective synthesis and SPR-based binding inhibition assays.
    Di Pietro S; Bordoni V; Iacopini D; Achilli S; Pineschi M; Thépaut M; Fieschi F; Crotti P; Di Bussolo V
    Bioorg Chem; 2021 Feb; 107():104566. PubMed ID: 33387733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noncarbohydrate glycomimetics and glycoprotein surrogates as DC-SIGN antagonists and agonists.
    Prost LR; Grim JC; Tonelli M; Kiessling LL
    ACS Chem Biol; 2012 Sep; 7(9):1603-8. PubMed ID: 22747463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High affinity sugar ligands of C-type lectin receptor langerin.
    Ota F; Hirayama T; Kizuka Y; Yamaguchi Y; Fujinawa R; Nagata M; Ismanto HS; Lepenies B; Aretz J; Rademacher C; Seeberger PH; Angata T; Kitazume S; Yoshida K; Betsuyaku T; Kida K; Yamasaki S; Taniguchi N
    Biochim Biophys Acta Gen Subj; 2018 Jul; 1862(7):1592-1601. PubMed ID: 29631057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and quantitative analysis of two independent binding modes of a small ligand responsible for DC-SIGN clustering.
    Guzzi C; Alfarano P; Sutkeviciute I; Sattin S; Ribeiro-Viana R; Fieschi F; Bernardi A; Weiser J; Rojo J; Angulo J; Nieto PM
    Org Biomol Chem; 2016 Jan; 14(1):335-44. PubMed ID: 26611567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Remote Secondary Binding Pocket Promotes Heteromultivalent Targeting of DC-SIGN.
    Wawrzinek R; Wamhoff EC; Lefebre J; Rentzsch M; Bachem G; Domeniconi G; Schulze J; Fuchsberger FF; Zhang H; Modenutti C; Schnirch L; Marti MA; Schwardt O; Bräutigam M; Guberman M; Hauck D; Seeberger PH; Seitz O; Titz A; Ernst B; Rademacher C
    J Am Chem Soc; 2021 Nov; 143(45):18977-18988. PubMed ID: 34748320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CellFy: A Cell-Based Fragment Screen against C-Type Lectins.
    Schulze J; Baukmann H; Wawrzinek R; Fuchsberger FF; Specker E; Aretz J; Nazaré M; Rademacher C
    ACS Chem Biol; 2018 Dec; 13(12):3229-3235. PubMed ID: 30480432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.